Lumos Diagnostics Holdings Ltd Gets $710K R&D Refund for Reader Platform
Lumos Diagnostics banks $709,837 R&D tax refund to fuel reader platform innovation
Lumos Diagnostics (ASX: LDX) has received a cash refund of A$709,837 under the Australian Government’s Research and Development (R&D) Tax Incentive for the FY25 financial year ended 30 June 2025.
The refund supports continued investment in the company’s proprietary diagnostic technology. It relates mainly to ongoing R&D on Lumos’ portable handheld and disposable reader technology platforms.
When big ASX news breaks, our subscribers know first
What the refund supports
The cash refund is primarily associated with R&D efforts focused on enhancing Lumos’ proprietary portable handheld and disposable reader technology platforms.
According to the company, these platforms support:
- Detection of a broader range of clinical biomarkers
- Improved interpretation of point-of-care test results
- Smooth integration with electronic medical records
These capabilities are described by Lumos as a key part of its value proposition. The company states they have played a significant role in securing contracts with partners including Hologic, Aptatek BioSciences and Micro-Pak.
The FDA CLIA waiver for FebriDx, secured in March 2026, expanded the addressable US market 15-fold to over US$1 billion by opening access to more than 300,000 point-of-care locations that previously required moderate-complexity laboratory certification.
CEO Commentary
“We are pleased to receive this R&D tax refund, which supports our ongoing investment in innovation and product development. The funding assists with the evolution of our proprietary reader platform – a core component of our diagnostics offering that continues to attract significant interest. We remain committed to advancing point-of-care technologies that deliver meaningful clinical outcomes,” said Doug Ward, CEO and Managing Director of Lumos Diagnostics.
How the R&D Tax Incentive works
The Australian Government’s Research and Development Tax Incentive provides eligible companies with cash refunds for up to 48.5% of eligible expenditure on R&D activities.
| Fact | Detail | Why it matters to investors |
|---|---|---|
| Refund received | A$709,837 | Supports ongoing investment in innovation |
| Financial year | FY25 (ended 30 June 2025) | Relates to prior-year eligible R&D spend |
| Incentive rate | Up to 48.5% of eligible R&D | Reduces net cost of ongoing innovation |
The next major ASX story will hit our subscribers first
Why it matters for the investment case
The refund supports Lumos’ core value proposition, its proprietary reader platform, which the company says underpins existing commercial partnerships. By offsetting a portion of R&D costs, it allows continued investment in the technology.
Ward reiterated the company’s commitment to advancing point-of-care technologies that deliver meaningful clinical outcomes. The funding is directed toward the continued evolution of the reader platform, which Lumos states continues to attract significant interest.
The reader platform’s commercial appeal is reflected in the US$317 million PHASE Scientific distribution deal secured earlier in FY26, a six-year exclusive US agreement that had already generated US$3.5 million in milestone cash at signing.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.